News

Minerva Announces Outcome of End-of-Phase 2 Meeting With FDA

WALTHAM, Mass., May 15, 2017 (GLOBE NEWSWIRE) — Following a recent “end-of-Phase 2” meeting with the U.S. Food and Drug Administration (FDA), Minerva Neurosciences, Inc. (NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced its plans to initiate Phase 3 development of MIN-101, a drug targeting negative symptoms in schizophrenia patients.  A pivotal Phase 3 trial with MIN-101 is expected to be initiated in the second half of 2017.

2017-06-20T16:12:06+00:00